MedTrace Logo

My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia

NCT00801580 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2009-09-15

No results posted yet for this study

Summary

The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C \[cytarabine\]).

Conditions

  • Lymphoid Leukemia

Interventions

DRUG

doxorubicin liposomal

* Cyclophosphamide * Mesna * Methotrexate * Doxorubicin liposomal * Vincristine * Dexamethasone * Rituximab * Cytarabine

Sponsors & Collaborators

  • University of Bologna

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00801580 on ClinicalTrials.gov